- |||||||||| Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
[VIRTUAL] OPTI-ON: A Longitudinal Real-World Study of Opicapone in Patients with Parkinson's disease and Motor Fluctuations () - Sep 29, 2021 - Abstract #MDSCongress2021MDS_Congress_688;
P
Results from the OPTI-ON study are expected to provide real-world information about the patterns of use and outcomes with adjunctive opicapone for treatment of PD in clinical practices throughout the US. These results will expand upon findings from the phase 3 clinical trials, which established the efficacy and safety of once-daily opicapone in patients with PD and OFF-episodes.
- |||||||||| Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
[VIRTUAL] Effects of Opicapone on Sleep in Patients with Parkinson's Disease and Motor Fluctuations () - Sep 29, 2021 - Abstract #MDSCongress2021MDS_Congress_671;
The addition of once-daily OPC 50 mg to LD/CD decreased the frequency of awakenings and WASO duration, although the effects were modest and limited by small sample sizes. More research is needed to better understand the effects of OPC on sleep in patients with PD who are experiencing motor fluctuations.
- |||||||||| Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
[VIRTUAL] Evaluating Patients' Preferences for Parkinson's Disease Treatments () - Sep 29, 2021 - Abstract #MDSCongress2021MDS_Congress_607;
Patient feedback provided valuable insights on patient preferences that will be incorporated into a future online survey. Patients indicated that OFF-episodes are not well-controlled with currently available medications, and this research contributes to the literature on patients' experiences with motor fluctuations to support identification of appropriate treatment strategies for OFF-episodes.
- |||||||||| carbidopa/levodopa / Generic mfg.
[VIRTUAL] Exploring local field potential changes in dystonic camptocormia () - Sep 29, 2021 - Abstract #MDSCongress2021MDS_Congress_403;
He was trialed on Artane, Sinemet, and botulinum toxin injections which did not yield satisfactory response... We postulate the 15Hz beta band to be a biomarker of camptocormia that has not previously been observed.
- |||||||||| [VIRTUAL] Central Pontine Myelinolysis related tremor effectively treated with Deep Brain Stimulation () - Sep 29, 2021 - Abstract #MDSCongress2021MDS_Congress_245;
In this case, a cerebellar tremor was related to cerebellar atrophy and extension of myelinolysis to the middle cerebellar peduncles. Traditionally, the VIM of the thalamus has been considered the main target for such medically intractable tremors (3) as in this case where marked improvement of tremor was achieved with DBS in the VIM.
- |||||||||| carbidopa/levodopa / Generic mfg.
[VIRTUAL] PLA2G6-Associated Neurodegeneration: A Continuum of Phenotypes () - Sep 29, 2021 - Abstract #MDSCongress2021MDS_Congress_193;
Features of multiple PLAN phenotypes can present in an individual without evidence of iron accumulation on brain imaging. PLA2G6 mutations should be investigated for young-onset neurodegenerative disease characterized by ophthalmoparesis, dysarthria, ataxia, and Parkinsonism.
- |||||||||| primidone / Generic mfg., carbidopa/levodopa / Generic mfg., propranolol / Generic mfg.
[VIRTUAL] Deep Brain Stimulation for the management of tremor in a child with Rett syndrome () - Sep 29, 2021 - Abstract #MDSCongress2021MDS_Congress_72;
Rett syndrome is a neurodevelopmental condition with numerous associated involuntary movements including stereotypy, tremor, chorea, myoclonus, ataxia, dystonia, and parkinsonism. Although this is a single case and no objective measures were used, our patient's improved tremor control and reports of increased hand usage suggest there may be a role of DBS in the management of tremor and possibly other movement disorders associated with Rett syndrome.
- |||||||||| carbidopa/levodopa / Generic mfg.
Review, Journal: Treatment Options for Motor and Non-Motor Symptoms of Parkinson's Disease. (Pubmed Central) - Sep 22, 2021
Therapy uses daily administration of either the dopamine precursor levodopa (with carbidopa) or a dopamine agonist, compounds that preserve residual dopamine, and other specific motor/non-motor-related compounds...In conclusion, the best strategy for treating PD is to hope to slow disorder progression and strive to achieve stability with neuroprotection. The ultimate goal of any management program is to improve the quality-of-life for a person with Parkinson's disease.
- |||||||||| galicaftor (GLPG2222) / AbbVie
Journal: Fueling the Pipeline via Innovations in Organic Synthesis. (Pubmed Central) - Sep 18, 2021
Examples of project contributions from neuroscience, cystic fibrosis, and virology illustrate the impact of the DSG approach. In the first ten years of innovative science in pursuit of excellence in synthesis, several advanced drug candidates, including ABBV-2222 (galicaftor) for cystic fibrosis and foslevodopa/foscarbidopa for Parkinson's disease, have emerged with key contributions from COS.
- |||||||||| carbidopa/levodopa / Generic mfg.
Clinical, Journal: Quality Improvement in Parkinson's Disease: A Successful Program to Enhance Timely Administration of Levodopa in the Hospital. (Pubmed Central) - Sep 17, 2021
In the first ten years of innovative science in pursuit of excellence in synthesis, several advanced drug candidates, including ABBV-2222 (galicaftor) for cystic fibrosis and foslevodopa/foscarbidopa for Parkinson's disease, have emerged with key contributions from COS. With multifaceted but relatively simple measures, we were able to "change the culture" so that hospitalized patients with Parkinson's disease receive levodopa on time.
- |||||||||| levodopa/carbidopa SC (ABBV-951) / AbbVie
Journal: Foslevodopa/foscarbidopa: a new subcutaneous treatment for Parkinson's disease. (Pubmed Central) - Sep 16, 2021
Preparation of foslevodopa and foscarbidopa enables preclinical and clinical PK, safety, and tolerability studies in support of their advancement for the treatment of PD. In Phase 1 clinical trials, foslevodopa/foscarbidopa demonstrates consistent and stable LD plasma exposure supporting further studies of this treatment as a potentially transformational option for those suffering from PD.
- |||||||||| Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
Journal: Ongentys (Opicapone): A New COMT Inhibitor for the Treatment of Parkinson's Disease. (Pubmed Central) - Sep 8, 2021
Our findings suggest that treatments modulating the gut microbiota may play a role in reducing the severity and progression of PD as well as ameliorating non-motor symptoms such as constipation. Opicapone is a safe and effective COMT inhibitor shown to reduce off episodes in patients with PD.
- |||||||||| Comtan (entacapone) / Novartis, Orion Corp
Journal: A Smartphone-Based Fluorescent Electronic Tongue for Tracing Dopaminergic Agents in Human Urine. (Pubmed Central) - Sep 5, 2021
Herein, visual and fingerprint fluorimetric patterns have been created by an optical sensor array to simultaneously detect and discriminate among levodopa, carbidopa, benserazide, and entacapone, as important dopaminergic agents...Different concentrations of the target analytes were excellently recognized in human urine. The high sensitivity of the array, which is a bonus to rapid, on-site, and visual discrimination of dopaminergic agents, holds great promise for routine analysis of real-world clinical samples.
- |||||||||| sarizotan (EMD128130) / Newron
Clinical, Review, Journal: Current Therapies in Clinical Trials of Parkinson's Disease: A 2021 Update. (Pubmed Central) - Aug 29, 2021
In 1970, the United States Food and Drug Administration approved the drug levodopa as a dopamine replacement to manage PD motor symptoms; levodopa-carbidopa combination became commercialized in 1975...The three phase-III trials use embryonic dopamine cell implant, 5-HT receptor agonist (sarizotan), and adenosine A receptor antagonist (caffeine)...Additionally, we discuss the most potent drug or therapy among these trials. By systematically updating the current trial status and analyzing the therapeutic strategies, we hope this review can provide new ideas and insights for PD therapy development.
- |||||||||| carbidopa/levodopa / Generic mfg., carbidopa / Generic mfg.
Clinical, Journal: Carbidopa and Levodopa Extended Release Capsules (Rytary®) in Patients with and without Troublesome and Non-Troublesome Dyskinesia. (Pubmed Central) - Aug 21, 2021
In the TD group, comparing CD-LD ER conversion to CD-LD IR optimization, benefits were still observed, but there was less reduction in OFF time, less reduction in troublesome dyskinesia, and fewer patients self-rated themselves much or very much improved than in the ND and NTDO groups. These data suggest that in clinical practice, the best chances for success with conversion from CD-LD IR to CD-LD ER are in patients without TD.
- |||||||||| Trial completion date, Trial primary completion date: Gait Analysis in Neurological Disease (clinicaltrials.gov) - Aug 18, 2021
P=N/A, N=120, Active, not recruiting,
These data suggest that in clinical practice, the best chances for success with conversion from CD-LD IR to CD-LD ER are in patients without TD. Trial completion date: Jun 2021 --> Jun 2023 | Trial primary completion date: Jun 2021 --> Jun 2023
- |||||||||| Duodopa (levodopa/carbidopa intraduodenal gel infusion) / AbbVie
Journal: Beyond 10 years of levodopa intestinal infusion experience: Analysis of mortality and its predictors. (Pubmed Central) - Aug 14, 2021
Trial completion date: Jun 2021 --> Jun 2023 | Trial primary completion date: Jun 2021 --> Jun 2023 Our findings do not indicate an association between SAEs or LCIG treatment duration and mortality and highlight the importance of cognitive alterations as a mortality predictor of LCIG patients.
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Journal: Dopamine D3 Receptors: From Bench to Bedside. (Pubmed Central) - Aug 11, 2021
Accordingly, D3 receptors constitute attractive targets for developing novel drugs for the improved treatment of different psychiatric and neurological disorders. (Neuropsychopharmacol Hung 2021; 23(2): 272-280).
- |||||||||| Kynmobi (apomorphine sublingual film) / Sumitomo Dainippon, Aquestive
Clinical, Journal: Patient Preferences for Treating "OFF" Episodes in Parkinson's Disease: A Discrete Choice Experiment. (Pubmed Central) - Jun 10, 2021
In a discrete choice experiment, US adults with self-reported PD of ≥5 years, or <5 years with "OFF" episodes, taking oral carbidopa/levodopa, selected between pairs of theoretical on-demand treatments that varied by mode of administration (with and without mode-specific adverse events [AEs]), time to FULL "ON," duration of "ON," and out-of-pocket cost for a 30-day supply...On average, respondents preferred a theoretical dissolvable sublingual film versus other theoretical treatments with alternative modes of administration. Respondents were willing to pay $28-$52 US dollars to switch from least- to more-preferred mode of administration with associated AEs, $58 to reach FULL "ON" in 15 versus 60 min, and $9 to increase duration of FULL "ON" from 1 to 2 h. Respondents with PD valued lower out-of-pocket cost and a sublingual mode of administration with its associated AEs when choosing an on-demand treatment for "OFF" episodes.
- |||||||||| carbidopa/levodopa / Generic mfg.
[VIRTUAL] Ubiquitin-positive Astrogliopathy Clinically Mimicking Parkinson’s Disease (Virtual Poster Gallery) - Jun 8, 2021 - Abstract #AANP2021AANP_3;
He presented initially with dysphagia then progressed to Sinemet-responsive Parkinsonism, leading to a clinical diagnosis of Parkinson’s disease...Unusually in this case, neuronal loss and ubiquitin pathology were not prominent in the substantia nigra despite the dopamine-responsive clinical symptoms. Further molecular studies are needed to gain insight into this rare neurodegenerative process.
- |||||||||| carbidopa/levodopa / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis (clinicaltrials.gov) - Jun 7, 2021
P1, N=15, Enrolling by invitation,
Further molecular studies are needed to gain insight into this rare neurodegenerative process. Suspended --> Enrolling by invitation | Trial completion date: May 2021 --> May 2022 | Trial primary completion date: May 2021 --> May 2022
- |||||||||| Trial completion date, Trial primary completion date: Neurobiological Drivers of Mobility Resilience: The Dopaminergic System (clinicaltrials.gov) - Jun 4, 2021
P1/2, N=14, Recruiting,
Suspended --> Enrolling by invitation | Trial completion date: May 2021 --> May 2022 | Trial primary completion date: May 2021 --> May 2022 Trial completion date: Apr 2021 --> Sep 2022 | Trial primary completion date: Apr 2021 --> Sep 2022
- |||||||||| carbidopa/levodopa / Generic mfg.
[VIRTUAL] Pharmacokinetic analysis of levodopa and carbidopa following subcutaneous infusion: A population pharmacokinetics model (Room Copenhagen) - May 30, 2021 - Abstract #EAN2021EAN_718;
Background and aims: ND0612 is an investigational subcutaneous delivery system providing minimally invasive, continuous infusion of liquid levodopa/carbidopa under development for reliable, sustained relief of motor fluctuations in people with Parkinson’s disease. Model diagnostics for the carbidopa and levodopa population PK models indicated a satisfactory predictive performance, supporting their usability to derive individual predictions of exposure to be used in future pharmacokinetic-pharmacodynamic analyses.
|
